Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Article in English | MEDLINE | ID: mdl-38156230

ABSTRACT

Chat Generative Pre-trained Transformer (ChatGPT), the flagship generative artificial intelligence (AI) chatbot by OpenAI, is transforming many things in medicine, from healthcare and research to medical education. It is anticipated to integrate in many aspects of the medical industry, and we should brace for this inevitability and use it to our advantage. Here are proposed ways you can use ChatGPT in medicine with some specific use cases in antimicrobial stewardship and hospital epidemiology.

3.
Gastroenterol Clin North Am ; 50(2): 415-430, 2021 06.
Article in English | MEDLINE | ID: mdl-34024449

ABSTRACT

Infectious gastroenteritis is common after transplantation and can lead to increased morbidity and mortality. A wide range of organisms can lead to gastroenteritis in this patient population. Clostridioides difficile, cytomegalovirus, and norovirus are the most common pathogens. Newer diagnostic methods, especially multiplex polymerase chain reaction, have increased the diagnostic yield of infectious etiologies. In this review, we describe the epidemiology and risk factors for common infectious pathogens leading to gastroenteritis.


Subject(s)
Gastroenteritis , Hematopoietic Stem Cell Transplantation , Norovirus , Organ Transplantation , Diarrhea , Gastroenteritis/diagnosis , Gastroenteritis/epidemiology , Gastroenteritis/etiology , Humans , Norovirus/genetics , Organ Transplantation/adverse effects
5.
Transl Res ; 183: 41-56, 2017 05.
Article in English | MEDLINE | ID: mdl-28068521

ABSTRACT

Antiretroviral therapy has revolutionized the care of people with human immunodeficiency virus (HIV) by reducing morbidity and mortality from acquired immunodeficiency syndrome-related conditions. Despite longer life expectancy, however, HIV-infected individuals continue to have a higher risk of death compared with the general population. This has been attributed to the increasing incidence of noncommunicable diseases, in particular, atherosclerotic cardiovascular diseases. This is driven, in part, by the emergence of metabolic disorders, particularly dyslipidemia, insulin resistance, and lipodystrophy, in those on antiretroviral therapy. The pathogenesis of these metabolic derangements is complex and multifactorial, and could be a consequence of an interplay between traditional age-related risk factors, HIV infection, antiretroviral therapy effects, and the inflammatory state and immune activation in this population. Understanding the contributions of each of these factors could not just impact the current management of these individuals and help mitigate the risk for premature cardiovascular disease, but also shape the future direction of research in HIV.


Subject(s)
Dyslipidemias/etiology , HIV Infections/complications , Insulin Resistance/physiology , Anti-HIV Agents/adverse effects , Anti-HIV Agents/classification , Anti-HIV Agents/pharmacology , Dyslipidemias/prevention & control , HIV Infections/epidemiology , HIV Infections/immunology , HIV Infections/virology , Humans
6.
Transpl Infect Dis ; 19(2)2017 Apr.
Article in English | MEDLINE | ID: mdl-28099778

ABSTRACT

Non-Candida opportunistic yeasts are emerging causes of bloodstream infection (BSI) in immunocompromised hosts. However, their clinical presentation, management, and outcomes in stem cell transplant (SCT) recipients are not well described. We report the first case to our knowledge of Pseudozyma BSI in a SCT recipient. He had evidence of cutaneous involvement, which has not been previously described in the literature. He became infected while neutropenic and receiving empiric micafungin, which is notable because Pseudozyma is reported to be resistant to echinocandins. He was successfully treated with the sequential use of liposomal amphotericin B and voriconazole. A review of the literature revealed nine reported instances of Pseudozyma fungemia. We performed a retrospective review of 3557 SCT recipients at our institution from January 2000 to June 2015 and identified four additional cases of non-Candida yeast BSIs. These include two with Cryptococcus, one with Trichosporon, and one with Saccharomyces. Pseudozyma and other non-Candida yeasts are emerging pathogens that can cause severe and disseminated infections in SCT recipients and other immunocompromised hosts. Clinicians should have a high degree of suspicion for echinocandin-resistant yeasts, if patients develop breakthrough yeast BSIs while receiving echinocandin therapy.


Subject(s)
Antifungal Agents/therapeutic use , Dermatomycoses/microbiology , Exanthema/microbiology , Fungemia/microbiology , Opportunistic Infections/microbiology , Ustilaginales/pathogenicity , Yeasts/pathogenicity , Adult , Amphotericin B/administration & dosage , Amphotericin B/therapeutic use , Antifungal Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Cryptococcus/isolation & purification , Cryptococcus/pathogenicity , Cytarabine/therapeutic use , Dermatomycoses/blood , Dermatomycoses/drug therapy , Dermatomycoses/pathology , Echinocandins/administration & dosage , Echinocandins/therapeutic use , Exanthema/blood , Exanthema/drug therapy , Exanthema/pathology , Fever/microbiology , Fungemia/drug therapy , Granulocyte Colony-Stimulating Factor/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Idarubicin/therapeutic use , Immunocompromised Host , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Lipopeptides/administration & dosage , Lipopeptides/therapeutic use , Male , Micafungin , Opportunistic Infections/blood , Opportunistic Infections/drug therapy , Retrospective Studies , Saccharomyces/isolation & purification , Saccharomyces/pathogenicity , Salvage Therapy/methods , Trichosporon/isolation & purification , Trichosporon/pathogenicity , Ustilaginales/isolation & purification , Vidarabine/analogs & derivatives , Vidarabine/therapeutic use , Voriconazole/administration & dosage , Voriconazole/therapeutic use , Yeasts/isolation & purification
7.
J Infect ; 74(2): 179-186, 2017 02.
Article in English | MEDLINE | ID: mdl-27777118

ABSTRACT

BACKGROUND: Staphylococcus lugdunensis is a coagulase-negative staphylococcus with similar virulence characteristics as Staphylococcus aureus. Whether S. lugdunensis causes infective endocarditis (IE) in a similar proportion of cases as S. aureus (reported to be 12.6% in a definitive multicenter prospective study) is unclear. METHODS: We conducted a retrospective cohort study of adult patients with at least one blood culture positive for S. lugdunensis at our institution from January 2006 to December 2014. We examined microbiology data, ascertained disease severity and determined the proportion of patients with definite or possible IE based on the 2000 Modified Duke Criteria. Because coagulase-negative staphylococci were routinely identified to the species level at our institution from 2012 onwards, we determined the proportion of patients with definite or possible IE before and after implementation of routine speciation. We also compared our results with reported proportions of IE among patients with S. lugdunensis bacteremia (SLB) in other institutions by conducting a systematic review of the scientific literature. Nonparametric bootstrapping methods were performed to determine 95% confidence intervals (CI) for proportions of IE in patients with SLB. RESULTS: Seventy-four patients with SLB were identified, of whom 64% (47/74) had sepsis by SIRS criteria, and 18% (13/74) had severe illness by Pittsburgh bacteremia score (PBS). Kaplan-Meier survival analysis showed that one-year survival among patients with severe illness was worse than patients with non-severe illness (p = 0.02). Fifteen percent (11/74) of patients had definite or possible IE (95% CI 6.8-23.0%). The proportion of SLB patients with definite or possible IE was 15.8% (6/38, 95% CI 5.3-28.9%) prior to routine speciation and 13.9% (5/36, 95% CI 2.8-27.8%) after routine speciation (p = 0.71). Among patients with at least two positive blood cultures for S. lugdunensis, 25% (10/40, 95% CI 12.5-40.0%) had IE. Systematic review of the literature yielded eight relevant retrospective studies. Of studies that included patients with one or more positive blood cultures for S. lugdunensis, the proportion of IE ranged from 6.3% to 27.0%. CONCLUSION: The proportion of definite or possible IE among patients with SLB is similar to the proportion of IE among patients with S. aureus bacteremia. The proportions of IE among patients with SLB at other institutions fall within the 95% CI yielded by bootstrapping. Our findings suggest that growth of S. lugdunensis in two separate blood cultures should prompt consideration of workup for IE.


Subject(s)
Bacteremia/microbiology , Endocarditis, Bacterial/epidemiology , Endocarditis, Bacterial/microbiology , Staphylococcal Infections/microbiology , Staphylococcus lugdunensis/isolation & purification , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/mortality , Cohort Studies , Endocarditis, Bacterial/drug therapy , Endocarditis, Bacterial/mortality , Female , Humans , Male , Middle Aged , Retrospective Studies , Severity of Illness Index , Staphylococcal Infections/drug therapy , Staphylococcal Infections/epidemiology , Staphylococcal Infections/mortality , Staphylococcus lugdunensis/pathogenicity , United States/epidemiology , Young Adult
8.
Am J Trop Med Hyg ; 93(5): 1068-9, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26324725

ABSTRACT

Hemophagocytic lymphohistiocytosis (HLH) and rhabdomyolysis are rare complications of typhoid fever from Salmonella enterica serovar Typhi. Herein, we describe the clinical features in a 21-year-old female from India who presented to the intensive care unit with fever, severe pancytopenia, and rhabdomyolysis.


Subject(s)
Lymphohistiocytosis, Hemophagocytic/complications , Rhabdomyolysis/complications , Salmonella typhi/isolation & purification , Typhoid Fever/complications , Disk Diffusion Antimicrobial Tests , Drug Combinations , Drug Resistance, Bacterial , Drug Therapy, Combination , Female , Fever , Humans , India , Lymphohistiocytosis, Hemophagocytic/drug therapy , Rhabdomyolysis/drug therapy , Salmonella typhi/drug effects , Sepsis , Sulfamethizole/therapeutic use , Treatment Outcome , Trimethoprim/therapeutic use , Typhoid Fever/drug therapy , Young Adult
9.
Anaerobe ; 34: 84-5, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25881498

ABSTRACT

We report two cases of bacteremia with Actinobaculum schaalii, a rarely reported, anaerobic, Gram-positive bacterium. The first case was a patient with renal cancer who developed pyelonephritis after cryoablation, and the second was a patient who developed sepsis after a urogenital procedure. Bacteremia resolved after administration of empiric antibiotic therapy.


Subject(s)
Actinomycetaceae/isolation & purification , Actinomycetales Infections/diagnosis , Actinomycetales Infections/pathology , Bacteremia/diagnosis , Bacteremia/pathology , Actinomycetaceae/classification , Actinomycetales Infections/drug therapy , Actinomycetales Infections/microbiology , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/microbiology , Bacteria, Anaerobic/classification , Bacteria, Anaerobic/isolation & purification , Female , Humans , Male , Middle Aged , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...